Para-probiotics for preterm neonates—The next frontier

Nutrients

Volumn 10, Issue 7, 2018, Pages

  Deshpande, Girish ^a,b   Athalye Jape, Gayatri ^c   Patole, Sanjay ^c  

^a NEPEAN HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c KING EDWARD MEMORIAL HOSPITAL   (Australia)

Author keywords

Infant; Newborn; Probiotics; Review; Sepsis

Indexed keywords

BACTERIAL DNA; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; LIPOTEICHOIC ACID; PROBIOTIC AGENT;

ANTIBIOTIC RESISTANCE; BIFIDOBACTERIUM; CRITICALLY ILL PATIENT; CYTOKINE PRODUCTION; HUMAN; IMMUNE RESPONSE; INFLAMMATION; LACTOBACILLUS; META ANALYSIS (TOPIC); MORTALITY; NECROTIZING ENTEROCOLITIS; NONHUMAN; NOTE; PREMATURITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEPSIS; ANIMAL; EVIDENCE BASED MEDICINE; GASTROINTESTINAL TRACT; GESTATIONAL AGE; INFANT; INFANT MORTALITY; INTESTINE FLORA; MICROBIOLOGY; NEWBORN; RISK FACTOR;

ANIMALS; ENTEROCOLITIS, NECROTIZING; EVIDENCE-BASED MEDICINE; GASTROINTESTINAL MICROBIOME; GASTROINTESTINAL TRACT; GESTATIONAL AGE; HUMANS; INFANT; INFANT MORTALITY; INFANT, NEWBORN; INFANT, PREMATURE; PREMATURE BIRTH; PROBIOTICS; RISK FACTORS; SEPSIS;

EID: 85049670569     PISSN: None     EISSN: 20726643     Source Type: Journal    
DOI: 10.3390/nu10070871     Document Type: Note

References (80)

1. Glass, H.C.; Costarino, A.T.; Stayer, S.A.; Brett, C.M.; Cladis, F.; Davis, P.J. Outcomes for extremely premature infants. Anesth. Analg. 2015, 120, 1337–1351. [CrossRef] [PubMed]
2. Hornik, C.P.; Fort, P.; Clark, R.H.; Watt, K.; Benjamin, D.K., Jr.; Smith, P.B.; Manzoni, P.; Jacqz-Aigrain, E.; Kaguelidou, F.; Cohen-Wolkowiez, M. Early and late onset sepsis in very-low-birth-weight infants from a large group of neonatal intensive care units. Early Hum. Dev. 2012, 88 (Suppl. 2), S69–S74. [CrossRef]
3. Mupsilonller, M.J.; Paul, T.; Seeliger, S. Necrotizing enterocolitis in premature infants and newborns. J. Neonatal Perinat. Med. 2016, 9, 233–242.
4. Nino, D.F.; Sodhi, C.P.; Hackam, D.J. Necrotizing enterocolitis: New insights into pathogenesis and mechanisms. Nat. Rev. Gastroenterol. Hepatol. 2016, 13, 590–600. [CrossRef] [PubMed]
5. Henry, M.C.; Moss, R.L. Neonatal necrotizing enterocolitis. Semin. Pediatr. Surg. 2008, 17, 98–109. [CrossRef] [PubMed]
6. Neu, J.; Walker, W.A. Necrotizing enterocolitis. N. Engl. J. Med. 2011, 364, 255–264. [CrossRef] [PubMed]
7. Schulzke, S.M.; Deshpande, G.C.; Patole, S.K. Neurodevelopmental outcomes of very low-birth-weight infants with necrotizing enterocolitis: A systematic review of observational studies. Arch. Pediatr. Adolesc. Med. 2007, 161, 583–590. [CrossRef] [PubMed]
8. Stey, A.; Barnert, E.S.; Tseng, C.H.; Keeler, E.; Needleman, J.; Leng, M.; Kelley-Quon, L.I.; Shew, S.B. Outcomes and costs of surgical treatments of necrotizing enterocolitis. Pediatrics 2015, 135, e1190–e1197. [CrossRef] [PubMed]
9. Food and Agriculture Organization (FAO); World Health Organization (WHO). Guidelines for the Evaluation of Probiotics in Food: Report of a Joint FAO/WHO Working Group on Drafting Guidelines for the Evaluation of Probiotics in Food 2002. Available online: ftp://ftp.fao.org/es/esn/food/wgreport2.pdf (accessed on 1 October 2017).
10. Rao, R.K.; Samak, G. Protection and Restitution of Gut Barrier by Probiotics: Nutritional and Clinical Implications. Curr. Nutr. Food Sci. 2013, 9, 99–107. [PubMed]
11. Walker, A. Intestinal colonization and programming of the intestinal immune response. J. Clin. Gastroenterol. 2014, 48 (Suppl. 1), S8–S11. [CrossRef] [PubMed]
12. Deshpande, G.; Rao, S.; Patole, S.; Bulsara, M. Updated meta-analysis of probiotics for preventing necrotizing enterocolitis in preterm neonates. Pediatrics 2010, 125, 921–930. [CrossRef] [PubMed]
13. AlFaleh, K.; Anabrees, J. Probiotics for prevention of necrotizing enterocolitis in preterm infants. Evid. Based Child. Health 2014, 9, 584–671. [CrossRef] [PubMed]
14. Deshpande, G.; Rao, S.; Patole, S. Probiotics in neonatal intensive care—Back to the future. Aust. N. Z. J. Obstet. Gynaecol. 2015, 55, 210–217. [CrossRef] [PubMed]
15. Hartel, C.; Pagel, J.; Rupp, J.; Bendiks, M.; Guthmann, F.; Rieger-Fackeldey, E.; Heckmann, M.; Franz, A.; Schiffmann, J.H.; Zimmermann, B.; et al. Prophylactic use of Lactobacillus acidophilus/Bifidobacterium infantis probiotics and outcome in very low birth weight infants. J. Pediatr. 2014, 165, 285–289. [CrossRef] [PubMed]
16. Janvier, A.; Malo, J.; Barrington, K.J. Cohort study of probiotics in a North American neonatal intensive care unit. J. Pediatr. 2014, 164, 980–985. [CrossRef] [PubMed]
17. Luoto, R.; Isolauri, E.; Lehtonen, L. Safety of Lactobacillus GG probiotic in infants with very low birth weight: Twelve years of experience. Clin. Infect. Dis. 2010, 50, 1327–1328. [CrossRef] [PubMed]
18. Patole, S.K.; Rao, S.C.; Keil, A.D.; Nathan, E.A.; Doherty, D.A.; Simmer, K.N. Benefits of Bifidobacterium breve M-16V Supplementation in Preterm Neonates—A Retrospective Cohort Study. PLoS ONE 2016, 11, e0150775. [CrossRef] [PubMed]
19. Olsen, R.; Greisen, G.; Schroder, M.; Brok, J. Prophylactic Probiotics for Preterm Infants: A Systematic Review and Meta-Analysis of Observational Studies. Neonatology 2016, 109, 105–112. [CrossRef] [PubMed]
20. Kataria, J.; Li, N.; Wynn, J.L.; Neu, J. Probiotic microbes: Do they need to be alive to be beneficial? Nutr. Rev. 2009, 67, 546–550. [CrossRef] [PubMed]
21. C.D.C. Fatal Gastrointestinal Mucormycosis in an Infant Following Ingestion of Contaminated Dietary Supplement—Connecticut. 2014. Available online: https://www.cdc.gov/fungal/outbreaks/rhizopus-investigation.html (accessed on 1 June 2018).
22. Jacobs, S.E.; Tobin, J.M.; Opie, G.F.; Donath, S.; Tabrizi, S.N.; Pirotta, M.; Morley, C.J.; Garland, S.M. Probiotic effects on late-onset sepsis in very preterm infants: A randomized controlled trial. Pediatrics 2013, 132, 1055–1062. [CrossRef] [PubMed]
23. Boyle, R.J.; Robins-Browne, R.M.; Tang, M.L. Probiotic use in clinical practice: What are the risks? Am. J. Clin. Nutr. 2006, 83, 1256–1264. [CrossRef] [PubMed]
24. Dani, C.; Coviello, C.C.; Corsini, I.I.; Arena, F.; Antonelli, A.; Rossolini, G.M. Lactobacillus Sepsis and Probiotic Therapy in Newborns: Two New Cases and Literature Review. AJP Rep. 2016, 6, e25–e29. [PubMed]
25. Jenke, A.; Ruf, E.M.; Hoppe, T.; Heldmann, M.; Wirth, S. Bifidobacterium septicaemia in an extremely low-birthweight infant under probiotic therapy. Arch. Dis. Child. Fetal Neonatal Ed. 2012, 97, F217–F218. [CrossRef] [PubMed]
26. Ohishi, A.; Takahashi, S.; Ito, Y.; Ohishi, Y.; Tsukamoto, K.; Nanba, Y.; Ito, N.; Kakiuchi, S.; Saitoh, A.; Morotomi, M.; et al. Bifidobacterium septicemia associated with postoperative probiotic therapy in a neonate with omphalocele. J. Pediatr. 2010, 156, 679–681. [CrossRef] [PubMed]
27. Broughton, R.A.; Gruber, W.C.; Haffar, A.A.; Baker, C.J. Neonatal meningitis due to Lactobacillus. Pediatr. Infect. Dis. 1983, 2, 382–384. [CrossRef] [PubMed]
28. Reddy, V.S.; Patole, S.K.; Rao, S. Role of probiotics in short bowel syndrome in infants and children—A systematic review. Nutrients 2013, 5, 679–699. [CrossRef] [PubMed]
29. Thompson, C.; McCarter, Y.S.; Krause, P.J.; Herson, V.C. Lactobacillus acidophilus sepsis in a neonate. J. Perinatol. 2001, 21, 258–260. [CrossRef] [PubMed]
30. Kopp, M.V.; Hennemuth, I.; Heinzmann, A.; Urbanek, R. Randomized, double-blind, placebo-controlled trial of probiotics for primary prevention: No clinical effects of Lactobacillus GG supplementation. Pediatrics 2008, 121, e850–e856. [CrossRef] [PubMed]
31. Mater, D.D.; Langella, P.; Corthier, G.; Flores, M.J. A probiotic Lactobacillus strain can acquire vancomycin resistance during digestive transit in mice. J. Mol. Microbiol. Biotechnol. 2008, 14, 123–127. [CrossRef] [PubMed]
32. Rosander, A.; Connolly, E.; Roos, S. Removal of antibiotic resistance gene carrying plasmids from Lactobacillus reuteri ATCC 55730 and characterization of the resulting daughter strain, L. reuteri DSM 17938. Appl. Environ. Microbiol. 2008, 74, 6032–6040. [CrossRef] [PubMed]
33. Zheng, M.; Zhang, R.; Tian, X.; Zhou, X.; Pan, X.; Wong, A. Assessing the risk of probiotic dietary supplements in the context of antibiotic resistance. Front. Microbiol. 2017, 8, 908. [CrossRef] [PubMed]
34. Adams, C.A. The probiotic paradox: Live and dead cells are biological response modifiers. Nutr. Res. Rev. 2010, 23, 37–46. [CrossRef] [PubMed]
35. Lahtinen, S. Probiotic viability-does it matter? Microb. Ecol. Health Dis. 2012, 23, 18567. [CrossRef] [PubMed]
36. Nighswonger, B.D.; Brashears, M.M.; Gilliland, S.E. Viability of Lactobacillus acidophilus and Lactobacillus casei in fermented milk products during refrigerated storage. J. Dairy Sci. 1996, 79, 212–219. [CrossRef]
37. Taverniti, V.; Guglielmetti, S. The immunomodulatory properties of probiotic microorganisms beyond their viability (ghost probiotics: Proposal of paraprobiotic concept). Genes Nutr. 2011, 6, 261–274. [CrossRef] [PubMed]
38. Zorzela, L.; Ardestani, S.K.; McFarland, L.V.; Vohra, S. Is there a role for modified probiotics as beneficial microbes: A systematic review of the literature. Benef. Microbes 2017, 8, 739–754. [CrossRef] [PubMed]
39. Li, N.; Russell, W.M.; Douglas-escobar, M.; Hauser, N.; Lopez, M.; Neu, J. Live and heat-killed Lactobacillus rhamnosus GG: Effects on proinflammatory and anti-inflammatory cytokines/chemokines in gastrostomy-fed infant rats. Pediatr. Res. 2009, 66, 203–207. [CrossRef] [PubMed]
40. Bloise, E.; Torricelli, M.; Novembri, R.; Borges, L.E.; Carrarelli, P.; Reis, F.M.; Petraglia, F. Heat-killed Lactobacillus rhamnosus GG modulates urocortin and cytokine release in primary trophoblast cells. Placenta 2010, 31, 867–872. [CrossRef] [PubMed]
41. Lopez, M.; Li, N.; Kataria, J.; Russell, M.; Neu, J. Live and ultraviolet-inactivated Lactobacillus rhamnosus GG decrease flagellin-induced interleukin-8 production in Caco-2 cells. J. Nutr. 2008, 138, 2264–2268. [CrossRef] [PubMed]
42. Zhang, L.; Li, N.; Caicedo, R.; Neu, J. Alive and dead Lactobacillus rhamnosus GG decrease tumor necrosis factor-alpha-induced interleukin-8 production in Caco-2 cells. J. Nutr. 2005, 135, 1752–1756. [CrossRef] [PubMed]
43. Guglielmetti, S.; Tamagnini, I.; Mora, D.; Minuzzo, M.; Scarafoni, A.; Arioli, S.; Hellman, J.; Karp, M.; Parini, C. Implication of an outer surface lipoprotein in adhesion of Bifidobacterium bifidum to Caco-2 cells. Appl. Environ. Microbiol. 2008, 74, 4695–4702. [CrossRef] [PubMed]
44. Sakai, Y.; Tsukahara, T.; Bukawa, W.; Matsubara, N.; Ushida, K. Cell preparation of Enterococcus faecalis strain EC-12 prevents vancomycin-resistant enterococci colonization in the cecum of newly hatched chicks. Poult. Sci. 2006, 85, 273–277. [CrossRef] [PubMed]
45. Ouwehand, A.C.; Tölkkö, S.; Kulmala, J.; Salminen, S.; Salminen, E. Adhesion of inactivated probiotic strains to intestinal mucus. Lett. Appl. Microbiol. 2000, 31, 82–86. [CrossRef] [PubMed]
46. Habil, N.; Abate, W.; Beal, J.; Foey, A.D. Heat-killed probiotic bacteria differentially regulate colonic epithelial cell production of human β-defensin-2: Dependence on inflammatory cytokines. Benef. Microbes 2014, 5, 483–495. [CrossRef] [PubMed]
47. Imaoka, A.; Shima, T.; Kato, K.; Mizuno, S.; Uehara, T.; Matsumoto, S.; Setoyama, H.; Hara, T.; Umesaki, Y. Anti-inflammatory activity of probiotic Bifidobacterium: Enhancement of IL-10 production in peripheral blood mononuclear cells from ulcerative colitis patients and inhibition of IL-8 secretion in HT-29 cells. World J. Gastroenterol. 2008, 14, 2511–2516. [CrossRef] [PubMed]
48. Donkor, O.N.; Ravikumar, M.; Proudfoot, O.; Day, S.L.; Apostolopoulos, V.; Paukovics, G.; Vasiljevic, T.; Nutt, S.L.; Gill, H. Cytokine profile and induction of T helper type 17 and regulatory T cells by human peripheral mononuclear cells after microbial exposure. Clin. Exp. Immunol. 2012, 167, 282–295. [CrossRef] [PubMed]
49. Szajewska, H.; Guarino, A.; Hojsak, I.; Indrio, F.; Kolacek, S.; Shamir, R.; Vandenplas, Y.; Weizman, Z. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. Use of probiotics for management of acute gastroenteritis: A position paper by the ESPGHAN Working Group for Probiotics and Prebiotics. J. Pediatr. Gastroenterol. Nutr. 2014, 58, 531–539. [CrossRef] [PubMed]
50. Sugahara, H.; Yao, R.; Odamaki, T.; Xiao, J.Z. Differences between live and heat-killed Bifidobacteria in the regulation of immune function and the intestinal environment. Benef. Microbes 2017, 8, 463–472. [CrossRef] [PubMed]
51. Schwendicke, F.; Horb, K.; Kneist, S.; Dörfer, C.; Paris, S. Effects of heat-inactivated Bifidobacterium BB12 on cariogenicity of Streptococcus mutans in vitro. Arch. Oral Biol. 2014, 59, 1384–1390. [CrossRef] [PubMed]
52. Hayes, C.L.; Natividad, J.M.; Jury, J.; Martin, R.; Langella, P.; Verdu, E.F. Efficacy of Bifidobacterium breve NCC2950 against DSS-induced colitis is dependent on bacterial preparation and timing of administration. Benef. Microbes 2014, 5, 79–88. [CrossRef] [PubMed]
53. Natividad, J.M.; Hayes, C.L.; Motta, J.P.; Jury, J.; Galipeau, H.J.; Philip, V.; Garcia-Rodenas, C.L.; Kiyama, H.; Bercik, P.; Verdu, E.F. Differential induction of antimicrobial REGIII by the intestinal microbiota and Bifidobacterium breve NCC2950. Appl. Environ. Microbiol. 2013, 79, 7745–7754. [CrossRef] [PubMed]
54. Nakamura, Y.; Terahara, M.; Iwamoto, T.; Yamada, K.; Asano, M.; Kakuta, S.; Iwakura, Y.; Totsuka, M. Upregulation of Polymeric Immunoglobulin Receptor Expression by the Heat-Inactivated Potential Probiotic Bifidobacterium bifidum OLB6378 in a Mouse Intestinal Explant Model. Scand. J. Immunol. 2012, 75, 176–183. [CrossRef] [PubMed]
55. Athalye-Jape, G.; Rao, S.; Simmer, K.; Patole, S. Bifidobacterium breve M-16V as a Probiotic for Preterm Infants: A Strain-Specific Systematic Review. J. Parenter. Enter. Nutr. 2017, 42, 677–688. [CrossRef] [PubMed]
56. Hikaru, U.; Koichi, S.; Yayoi, S.; Hiromichi, S.; Hiraoki, S.; Yoshikazu, O.; Seigo, S.; Satoru, N.; Toshiaki, S.; Yuichiro, Y. Bifidobacteria prevents preterm infants from infection and sepsis. Int. J. Probiotics Prebiotics 2010, 5, 33–36.
57. Fujii, T.; Ohtsuka, Y.; Lee, T.; Kudo, T.; Shoji, H.; Sato, H.; Nagata, S.; Shimizu, T.; Yamashiro, Y. Bifidobacterium breve enhances transforming growth factor beta1 signaling by regulating Smad7 expression in preterm infants. J. Pediatr. Gastroenterol. Nutr. 2006, 43, 83–88. [CrossRef] [PubMed]
58. Hood, S.K.; Zottola, E.A. Effect of low pH on the ability of Lactobacillus acidophilus to survive and adhere to human intestinal cells. J. Food Sci. 1988, 53, 1514–1516. [CrossRef]
59. Tuomola, E.M.; Ouwehand, A.C.; Salminen, S.J. Chemical, physical and enzymatic pre-treatments of probiotic lactobacilli alter their adhesion to human intestinal mucus glycoproteins. Int. J. Food Microbiol. 2000, 60, 75–81. [CrossRef]
60. Maldonado Galdeano, C.; Perdigon, G. Role of viability of probiotic strains in their persistence in the gut and in mucosal immune stimulation. J. Appl. Microbiol. 2004, 97, 673–681. [CrossRef] [PubMed]
61. Chauviere, G.; Coconnier, M.H.; Kerneis, S.; Darfeuille-Michaud, A.; Joly, B.; Servin, A.L. Competitive exclusion of diarrheagenic Escherichia coli (ETEC) from human enterocyte-like Caco-2 cells by heat-killed Lactobacillus. FEMS Microbiol. Lett. 1992, 70, 213–217. [CrossRef]
62. Montalto, M.; Maggiano, N.; Ricci, R.; Curigliano, V.; Santoro, L.; Di Nicuolo, F.; Vecchio, F.M.; Gasbarrini, A.; Gasbarrini, G. Lactobacillus acidophilus protects tight Sajunctions from aspirin damage in HT-29 cells. Digestion 2004, 69, 225–228. [CrossRef] [PubMed]
63. Yan, F.; Polk, D.B. Probiotic bacterium prevents cytokine-induced apoptosis in intestinal epithelial cells. J. Biol. Chem. 2002, 277, 50959–50965. [CrossRef] [PubMed]
64. Solis Pereyra, B.; Lemonnier, D. Induction of human cytokines by bacteria used in dairy foods. Nutr. Res. 1993, 13, 1127–1140. [CrossRef]
65. Matsuguchi, T.; Takagi, A.; Matsuzaki, T.; Nagaoka, M.; Ishikawa, K.; Yokokura, T.; Yoshikai, Y. Lipoteichoic acids from Lactobacillus strains elicit strong tumor necrosis factor alpha-inducing activities in macrophages through Toll-like receptor 2. Clin. Diagn. Lab. Immunol. 2003, 10, 259–266. [CrossRef] [PubMed]
66. Rachmilewitz, D.; Karmeli, F.; Takabayashi, K.; Hayashi, T.; LeiderTrejo, L.; Lee, J.; Leoni, L.M.; Raz, E. Immunostimulatory DNA ameliorates experimental and spontaneous murine colitis. Gastroenterology 2002, 122, 1428–1441. [CrossRef] [PubMed]
67. Takahashi, N.; Kitazawa, H.; Iwabuchi, N.; Xiao, J.Z.; Miyaji, K.; Iwatsuki, K.; Saito, T. Immunostimulatory oligodeoxynucleotide from Bifidobacterium longum suppresses Th2 immune responses in a murine model. Clin. Exp. Immunol. 2006, 145, 130–138. [CrossRef] [PubMed]
68. Konstantinov, S.R.; Smidt, H.; de Vos, W.M.; Bruijns, S.C.; Singh, S.K.; Valence, F.; Molle, D.; Lortal, S.; Altermann, E.; Klaenhammer, T.R.; et al. S layer protein A of Lactobacillus acidophilus NCFM regulates immature dendritic cell and T cell functions. Proc. Natl. Acad. Sci. USA 2008, 105. [CrossRef] [PubMed]
69. Kotani, Y.; Shinkai, S.; Okamatsu, H.; Toba, M.; Ogawa, K.; Yoshida, H.; Fukaya, T.; Fujiwara, Y.; Chaves, P.H.; Kakumoto, K.; et al. Oral intake of Lactobacillus pentosus strain b240 accelerates salivary immunoglobulin A secretion in the elderly: A randomized, placebo-controlled, double-blind trial. Immun. Ageing 2010, 7, 11. [CrossRef] [PubMed]
70. Hirose, Y.; Murosaki, S.; Yamamoto, Y.; Yoshikai, Y.; Tsuru, T. Daily intake of heat-killed Lactobacillus plantarum L-137 augments acquired immunity in healthy adults. J. Nutr. 2006, 136, 3069–3073. [CrossRef] [PubMed]
71. Van Baarlen, P.; Troost, F.J.; van Hemert, S.; van der, M.C.; de Vos, W.M.; de Groot, P.J.; Hooiveld, G.J.; Brummer, R.J.; Kleerebezem, M. Differential NF-kappaB pathways induction by Lactobacillus plantarum in the duodenum of healthy humans correlating with immune tolerance. Proc. Natl. Acad. Sci. USA 2009, 106. [CrossRef] [PubMed]
72. Haller, D.; Blum, S.; Bode, C.; Hammes, W.P.; Schiffrin, E.J. Activation of human peripheral blood mononuclear cells by nonpathogenic bacteria in vitro: Evidence of NK cells as primary targets. Infect. Immun. 2000, 68, 752–759. [CrossRef] [PubMed]
73. Korhonen, R.; Korpela, R.; Saxelin, M.; Maki, M.; Kankaanranta, H.; Moilanen, E. Induction of nitric oxide synthesis by probiotic Lactobacillus rhamnosus GG in J774 macrophages and human T84 intestinal epithelial cells. Inflammation 2001, 25, 223–232. [CrossRef] [PubMed]
74. Perdigon, G.; de Macias, M.E.; Alvarez, S.; Oliver, G.; de Ruiz Holgado, A.A. Effect of perorally administered lactobacilli on macrophage activation in mice. Infect. Immun. 1986, 53, 404–410. [PubMed]
75. Gill, H.S.; Rutherfurd, K.J. Viability and dose-response studies on the effects of the immunoenhancing lactic acid bacterium Lactobacillus rhamnosus in mice. Br. J. Nutr. 2001, 86, 285–289. [CrossRef] [PubMed]
76. De Simone, C.; Vesely, R.; Negri, R.; Bianchi Salvadori, B.; Zanzoglu, S.; Cilli, A.; Lucci, L. Enhancement of immune response of murine Peyer’s patches by a diet supplemented with yogurt. Immunopharmacol. Immunotoxicol. 1987, 9, 87–100. [CrossRef] [PubMed]
77. Perdigon, G.; Alvarez, S.; Rachid, M.; Aguero, G.; Gobbato, N. Immune system stimulation by probiotics. J. Dairy Sci. 1995, 78, 1597–1606. [CrossRef]
78. Ibnou-Zekri, N.; Blum, S.; Schiffrin, E.J.; von der Weid, T. Divergent patterns of colonization and immune response elicited from two intestinal Lactobacillus strains that display similar properties in vitro. Infect. Immun. 2003, 71, 428–436. [CrossRef] [PubMed]
79. Mohamadzadeh, M.; Olson, S.; Kalina, W.V.; Ruthel, G.; Demmin, G.L.; Warfield, K.L.; Bavari, S.; Klaenhammer, T.R. Lactobacilli activate human dendritic cells that skew T cells toward T helper 1 polarization. Proc. Natl. Acad. Sci. USA 2005, 102, 288–305. [CrossRef] [PubMed]
80. Lahtinen, S.J.; Gueimonde, M.; Ouwehand, A.C.; Reinikainen, J.P.; Salminen, S.J. Probiotic bacteria may become dormant during storage. Appl. Environ. Microbiol. 2005, 71, 1662–1663. [CrossRef] [PubMed]